Yoshida T, Kawai T, Hagiwara K, Yanagida K, Noda M, Tokura Y, Yoshimura I, Kaneko T, Nakagawa T. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy. Jpn J Clin Oncol. 2024;54(4):498-503. doi: 10.1093/jjco/hyad190.
Noda M, Kawai T, Hagiwara K, Yoshida T, Yanagida K, Tokura Y, Yoshimura I, Kaneko T, Nakagawa T. Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer. Glob Health Med. 2024 Jun 30;6(3):199-203. doi: 10.35772/ghm.2024.01019.
Taguchi S, Sugawara K, Gonoi W, Hanaoka S, Shiomi S, Kishitani K, Uemura Y, Akamatsu N, Inui S, Tanaka K, Yagi K, Kawai T, Nakagawa T, Fukuhara H, Abe O, Seto Y, Gonzalez MC, Prado CM, Kume H. The importance of ethnic-specific cut-offs of low muscle mass for survival prediction in oncology. Clin Nutr. 2024 Jan;43(1):134-141. doi: 10.1016/j.clnu.2023.11.029. Epub 2023 Nov 28.
Noda M, Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Yamashita H, Nakagawa K, Abe O, Fukuhara H, Kume H. Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis. Strahlenther Onkol. 2024 Aug;200(8):676-683. doi: 10.1007/s00066-023-02192-5. Epub 2024 Jan 5.
Yamada Y, Fujii Y, Kakutani S, Kimura N, Sugimoto K, Hakozaki Y, Sugihara T, Takeshima Y, Kawai T, Nakamura M, Kamei J, Taguchi S, Akiyama Y, Sato Y, Yamada D, Urabe F, Miyazaki H, Enomoto Y, Fukuhara H, Nakagawa T, Fujimura T, Kume H. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy. Sci Rep. 2024;14:7607. doi: 10.1038/s41598-024-58279-1.
Tsumura K, Fujimoto M, Tian Y, Fujimoto H, Maeshima AM, Nakagawa T, Kume H, Yoshida T, Kanai Y, Arai E. Aberrant cell adhesiveness due to DNA hypermethylation of KLF11 in papillary urothelial carcinomas. Exp Mol Pathol. 2024:137:104908. doi: 10.1016/j.yexmp.2024.104908.
Kawai T, Onozawa M, Taguchi S, Shiota M, Sakamoto S, Yamamoto Y, Kitagawa Y, Nakagawa T, Hinotsu S, Kume H, Japan Study Group of Prostate Cancer (J-CaP). Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: A nationwide multi-institutional study. Jpn J Clin Oncol. 2024;54(9):1045-51. doi: 10.1093/jjco/hyae079.
Sugawara K, Taguchi S, Gonoi W, Hanaoka S, Shiomi S, Kishitani K, Uemura Y, Akamatsu N, Inui S, Tanaka K, Yagi K, Kawai T, Nakagawa T, Fukuhara H, Abe O, Kume H, Gonzalez MC, Prado CM, Seto Y. Integrated impact of multiple body composition parameters on overall survival in gastrointestinal or genitourinary cancers: A descriptive cohort study. J Parenter Enteral Nutr. 2024;48:746-55.
Kobayashi K, Takahashi S, Yasuda M, Miyazaki J, Wada K, Matsumoto M, Hayami H, Yamamoto S, Kiyota H, Sato J, Matsumoto T, Hasegawa N, Kobayashi I, Masumori N, Kimura T, Yamada H, Nakagawa T, Kaneko T, Matsumoto K, Fujimura T, Kamei J, Ishikawa K, Fujimoto K, Nakai Y, Shigemura K, Sadahira T, Hinata N, Kitano H, Yamashita M, Yasufuku T, Komeda H, Hiyama Y, Takahashi Y, Kanamaru S, Murakami M, Arakawa S, Yamada D, Mita K, Hamasuna R, Tanaka K, Matsukawa M, Takaoka E, Shigeta M, Takenaka T, Nishino M, Ishitoya S, Hayakawa S, Okumura K, Ueda M. Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections. J Infect Chemother. 2024 Jul;30(7):579-589. doi: 10.1016/j.jiac.2024.03.024.
Oshina T, Yamada Y, Fujimura T, Taguchi S, Akiyama Y, Kamei J, Kaneko T, Kawai T, Obinata D, Yamada D, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Oncologic and functional outcomes of salvage robot-assisted radical prostatectomy: report of the first 10 cases. Curr Oncol. 2024 Aug 20;31(8):4762-4768. doi: 10.3390/curroncol31080356.
Fujita K, Matsushita Y, Toyoda S, Kojima T, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Nakamura E, Kaneko T, Kitano G, Motoshima T, Shiraishi Y, Kira S, Murashima T, Hara H, Matsumura M, Nishiyama N, Miyake H, Kitamura H, Uemura H. The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy. World J Urol. 2024 Sep 26;42(1):536. doi: 10.1007/s00345-024-05252-2.
Tanegashima T, Shiota M, Kimura T, Takamatsu D, Matsui Y, Yokomizo A, Saito R, Morizane S, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Edamura K, Narita S, Yamaguchi T, Kasahara T, Hashimoto K, Kato M, Yoshino T, Akamatsu S, Matsukawa A, Kaneko T, Matsumoto R, Joraku A, Kato M, Saito T, Kato T, Tatarano S, Sakamoto S, Kanno H, Terada N, Nishiyama N, Kitamura H, Eto M. Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement. Int J Clin Oncol. 2024 Oct;29(10):1586-1593. doi: 10.1007/s10147-024-02580-6.
Sakamoto S, Sato K, Kimura T, Matsui Y, Shiraishi Y, Hashimoto K, Miyake H, Narita S, Miki J, Matsumoto R, Kato T, Saito T, Tomida R, Shiota M, Joraku A, Terada N, Suekane S, Kaneko T, Tatarano S, Yoshio Y, Yoshino T, Nishiyama N, Kawakami E, Ichikawa T, Kitamura H. PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer. Sci Rep. 2024 Jul 3;14(1):15307. doi: 10.1038/s41598-024-65969-3.
Tomida R, Takahashi M, Matsushita Y, Kojima T, Yamana K, Kandori S, Bando Y, Nishiyama N, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Matsuda A, Kaneko T, Motoshima T, Shiraishi Y, Kira S, Murashima T, Hara H, Matsumura M, Kitamura H, Miyake H, Furukawa J. Comparison of Cabozantinib and Axitinib as second-line therapy after Nivolumab plus Ipilimumab in patients with metastatic clear cell renal cell carcinoma: A comparative analysis of retrospective real-world data. Clin Genitourin Cancer. 2024 Jun;22(3):102094. doi: 10.1016/j.clgc.2024.102094.
Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M. Prognostication in lymph node-positive prostate cancer with no PSA persistence after radical prostatectomy. Ann Surg Oncol. 2024 Jun;31(6):3872-3879. doi: 10.1245/s10434-024-14999-2.
英文、Case Reports
Yanagida K, Kawai T, Seito T, Matsumoto K, Kaneko T, Nakagawa T. Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma: A case report. IJU Case Rep. 2024;7(4):316–319. doi:10.1002/iju5.12734.
Goto M, Kaneko T, Yamamine N, Yanagida K, Noda M, Tokura Y, Yoshimura I, Kawai T, Nakagawa T. Vesicovaginal fistula and bladder calculus formation secondary to long-term retention of an intrauterine device. IJU Case Rep. 2024;7(5):355–358.
Arai S, Matsui R, Ono W, Asakawa S, Yamazaki O, Tamura Y, Terasaki M, Hagiwara K, Nakagawa T, Ohashi R, Shimizu A, Shibata S, Fujigaki Y. Discontinuing hemodialysis through corticosteroid treatment in a patient with cryofibrinogen-associated glomerulonephritis. Intern Med. 2024;63(13):1899–1905. doi:10.2169/internalmedicine.2897-23.
Yasui M, Kikuchi Y, Mikami Y, Kiyokawa T, Miyai K, Tsuchiya M, Watabe S, Kaneko T, Kawai T, Nakagawa T, Sasajima Y, Uozaki H. Malignant Sertoli-Leydig cell tumor with CTNNB1 mutation arising in a cryptorchid testis. Mod Pathol. 2024;37(10):100587. doi:10.1016/j.modpat.2024.100587.
英文、Review Article
Taguchi S, Kawai T, Nakagawa T, Kume H. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: A narrative review. Jpn J Clin Oncol. 2024 Mar 9;54(3):254–264. doi:10.1093/jjco/hyad172.
英文、Letter
Taguchi S, Kawai T, Nakagawa T, Kume H. Is there a role for pembrolizumab beyond progression in urothelial carcinoma? BJU Int. 2024 Jul;134(1):43–44. doi:10.1111/bju.16245. Epub 2023 Dec 18.
Kawai T, Taguchi S, Nozaki K, Kimura N, Oshina T, Iwaki T, Matsui H, Niimi A, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Kaneko T, Sawayanagi S, Nakayama H, Minamimoto R, Yamashita H, Miyazaki H, Fujimura T, Nakagawa T, Kume H. Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer. Prostate Int. 2023;11(4):239-246. doi: 10.1016/j.prnil.2023.10.002.
Akiyama Y, Niimi A, Nomiya A, Taguchi S, Yamada Y, Sato Y, Kawai T, Yamada D, Kume H, Homma Y. Efficacy and safety of intravesical dimethyl sulfoxide treatment for patients with refractory Hunner-type interstitial cystitis: Real-world data postofficial approval in Japan. Int J Urol, in press. doi: 10.1111/iju.15320.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. Int J Urol. 2023;30(12):1180-1186. doi: 10.1111/iju.15300.
Kaneko K, Yasuda M, Fukuuchi T, Yamaoka N, Takahashi K, Mawatari KI, Isotani S, Horie S, Nakagawa T. Plasma levels and urinary excretion of protein Z in patients with urolithiasis. Int J Urol. 2023;30(12):1188-1193. doi: 10.1111/iju.15277.
Takahashi S, Takada I, Hashimoto K, Yokoyama A, Nakagawa T, Makishima M, Kume H. ESS2 controls prostate cancer progression through recruitment of chromodomain helicase DNA binding protein 1. Sci Rep. 2023;13(1):12355. doi: 10.1038/s41598-023-39626-0.
Taguchi S, Onozawa M, Hinotsu S, Kawai T, Mitomi T, Uno S, Kume H. A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy. Jpn J Clin Oncol. 2023;53(10):957-965. doi: 10.1093/jjco/hyad068.
Tokura Y, Kawai T, Takei K, Ujiie T, Kanatani A, Yamada Y, Kaneko T, Kamai T, Nakagawa T. Geriatric 8 and Vulnerable Elders Survey-13 predict length of hospital stay and postoperative complications in Japanese patients undergoing urological surgery. J Geriatr Oncol. 2023;14(6):101558. doi: 10.1016/j.jgo.2023.101558.
Kimura T, Ishikawa H, Nagumo Y, Sekino Y, Kageyama Y, Ushijima H, Kawai T, Yamashita H, Azuma H, Nihei K, Takemura M, Hashimoto K, Maruo K, Tsuzuki T, Nishiyama H; BPT-ART Investigators Group. Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2023;117(3):644-651. doi: 10.1016/j.ijrobp.2023.05.013.
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. Immunotherapy. 2023;15(11):827-837. doi: 10.2217/imt-2023-0028.
Kaneko T, Yanagida K, Matsui K, Kawai T, Yamada Y, Ishii K, Kurozumi T, Suzuki T, Watanabe Y, Kawano H, Sakamoto T, Nakagawa T. Predictive Factors of Lower Urinary Tract Injuries and Spontaneous Voiding Failure After Pelvic Fractures. In Vivo. 2023;37(3):1323-1327. doi: 10.21873/invivo.13212.
Iwaki T, Akiyama Y, Nosato H, Kinjo M, Niimi A, Taguchi S, Yamada Y, Sato Y, Kawai T, Yamada D, Sakanashi H, Kume H, Homma Y, Fukuhara H. Deep Learning Models for Cystoscopic Recognition of Hunner Lesion in Interstitial Cystitis. Eur Urol Open Sci. 2023;49:44-50. doi: 10.1016/j.euros.2022.12.012.
Hakozaki Y, Yamada Y, Takeshima Y, Taguchi S, Kawai T, Nakamura M, Iwaki T, Teshima T, Kinoshita Y, Akiyama Y, Sato Y, Yamada D, Suzuki M, Kume H. Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients. Sci Rep. 2023;13(1):2672. doi: 10.1038/s41598-023-29634-5.
Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Taguchi S, Tabata M, Kaneko T, Ishikawa A, Miyazaki H, Kondo Y, Matsumoto A, Naito A, Hikatsu M, Fujii Y, Akiyama Y, Yamada Y, Sato Y, Nomiya A, Yamada D, Murata T, Suzuki M, Enomoto Y, Nishimatsu H, Takeuchi T, Tanaka Y, Kume H. Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study. World J Urol. 2023;41(3):767-776. doi: 10.1007/s00345-023-04300-7.
英文、Case Reports
Yanagida K, Kaneko T, Saito K, Yamamoto M, Yamamoto A, Yamada Y, Nakagawa T. Retroperitoneal capillary arteriovenous malformation mimicking a malignant neoplasm. IJU Case Rep. 2023;6(6):398-401. doi: 10.1002/iju5.12632.
Arai S, Matsui R, Ono W, Asakawa S, Yamazaki O, Tamura Y, Terasaki M, Hagiwara K, Nakagawa T, Ohashi R, Shimizu A, Shibata S, Fujigaki Y. Discontinuing Hemodialysis through Corticosteroid Treatment in a Patient with Cryofibrinogen-associated Glomerulonephritis. Intern Med. 2023, in press. doi: 10.2169/internalmedicine.2897-23.
Seito T, Kaneko T, Kawai T, Noda M, Tokura Y, Yoshimura I, Yasui M, Kikuchi Y, Sasajima Y, Nakagawa T. Solitary Fibrous Tumor in the Retroperitoneal Space Arising from the Diaphragm. In Vivo. 2023;37(6):2849-2853. doi: 10.21873/invivo.13401.
Yanagida K, Watanabe D, Yoshida T, Kawae N, Mizushima A, Nakagawa T. Obstructive urosepsis caused by ureterosciatic hernia: A case report. Urol Case Rep. 2023;47:102372. doi: 10.1016/j.eucr.2023.102372.
英文、総説
Taguchi S, Kawai T, Nakagawa T, Kume H. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review. Jpn J Clin Oncol. 2023, in press. doi: 10.1093/jjco/hyad172.
英文、Letter
Taguchi S, Kawai T, Nakagawa T, Kume H. Is there a role for pembrolizumab beyond progression in urothelial carcinoma? BJU Int. 2023, in press. doi: 10.1111/bju.16245.
2022年
英文、原著論文
Oshina T, Taguchi S, Miyakawa J, Akiyama Y, Sato Y, Kawai T, Fukuhara H, Nakagawa T, Kume H. Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction. Jpn J Clin Oncol. 2022;52(1):65-72. doi: 10.1093/jjco/hyab143.
Hagiwara K, Sakamoto A, Sasaki K, Kanatani A, Kimura M, Kaneko T, Takahashi S, Yamada Y, Nakagawa T. Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy. Jpn J Clin Oncol. 2022;52(1):73-80. doi: 10.1093/jjco/hyab147.
Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Takahashi S, Kume H. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: A multicenter retrospective study using time-dependent analysis. J Immunother Cancer. 2022;10(2):e003965. doi: 10.1136/jitc-2021-003965.
Akiyama Y, Niimi A, Igawa Y, Nomiya A, Yamada Y, Sato Y, Kawai T, Yamada D, Kume H, Homma Y. Cystectomy for patients with Hunner-type interstitial cystitis at a tertiary referral center in Japan. Low Urin Tract Symptoms. 2022;14(2):102-108. doi: 10.1111/luts.12416.
Kaneko T, Yanagida K, Matsui K, Kimura M, Yamada Y, Ishii K, Kurozumi T, Suzuki T, Watanabe Y, Kawano H, Sakamoto T, Nakagawa T. Incidence of genitourinary injuries in pelvic fractures: a 12-year single-center retrospective study. Neurourol Urodyn. 2022;41(4):1025-1030. doi: 10.1002/nau.24919.
Teshima T, Kobayashi Y, Kawai T, Kushihara Y, Nagaoka K, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Tanaka N, Tsunoda T, Kume H, Kakimi K. Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma. Oncol Lett. 2022;24(2):265. doi: 10.3892/ol.2022.13384.
Kobayashi K, Matsuyama H, Kawai T, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Komura K, Abe T, Kume H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Inoue K, Mitsui T, Kawakita M, Ohyama C, Mizokami A, Kuroiwa H. Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). Int J Urol. 2022;29(7):632-638. doi: 10.1111/iju.14854.
Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group. Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer. Cancer Sci. 2022;113(7):2386-2396. doi: 10.1111/cas.15383.
Takada I, Hidano S, Takahashi S, Yanaka K, Ogawa H, Tsuchiya M, Yokoyama A, Sato S, Ochi H, Nakagawa T, Kobayashi T, Nakagawa S, Makishima M. Ess2 controls survival of post-thymic CD4+ T cells through the Myc and IL-7 signaling pathways. J Biol Chem. 2022;298(9):102342. doi: 10.1016/j.jbc.2022.102342.
Hakozaki Y, Yamada Y, Kawai T, Nakamura M, Takeshima Y, Iwaki T, Teshima T, Kinoshita Y, Fujii Y, Akiyama Y, Sato Y, Yamada D, Suzuki M, Kashiwagi-Hakozaki M, Ushiku T, Kume H. Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer. Sci Rep. 2022;12(1):16202. doi: 10.1038/s41598-022-20319-z.
Nakamura M, Yamada Y, Sato Y, Honda K, Yamada D, Kawai T, Akiyama Y, Suzuki M, Kume H. Preservation of pelvic floor muscles contributes to early continence recovery after robot-assisted radical prostatectomy. PLoS One. 2022;17(10):e0275792. doi: 10.1371/journal.pone.0275792.
Takeshima Y, Yamada Y, Takemura K, Kimura N, Hakozaki Y, Miyakawa J, Taguchi S, Akiyama Y, Sato Y, Kawai T, Yamada D, Fujimura T, Kume H. The association between the parameters of uroflowmetry and lower urinary tract symptoms in prostate cancer patients after robot-assisted radical prostatectomy. PLoS One. 2022;17(10):e0275069. doi: 10.1371/journal.pone.0275069.
Sugimoto K, Taguchi S, Kishitani K, Kawai T, Masuda K, Nakamura Y, Kinjo M, Tambo M, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Fukuhara H, Kume H. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma. BMC Urol. 2022;22(1):177. doi: 10.1186/s12894-022-01139-9.
Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Honda S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuhara H, Takahashi S, Kume H. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003–2011) and a more recent period (2016–2020). Int J Urol. 2022;29(12):1462-1469. doi: 10.1111/iju.15014.
Negishi T, Nakagawa T, Nishiyama N, Kitamura H, Okajima E, Furubayashi N, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, Nakamura M. Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Jpn J Clin Oncol. 2022;52(12):1430-1435. doi: 10.1093/jjco/hyac144.
英文、Case Reports
Ujiie T, Kawai T, Kaneko T, Yamamoto T, Oshima Y, Fujikura M, Akiyama N, Sasajima Y, Tashiro H, Nakagawa T. Primary diffuse large B cell lymphoma of the prostate in a patient with HIV infection. IJU Case Rep. 2022;6(1):30-32. doi: 10.1002/iju5.12541.
2021年
英文、原著論文
Taguchi S, Nakagawa T, Uemura Y, Akamatsu N, Gonoi W, Naito A, Kawai T, Kume H, Fukuhara H. Comparison of Major Definitions of Sarcopenia Based on the Skeletal Muscle Index in Patients with Urothelial Carcinoma. Future Oncol. 2021;17(2):197-203. doi: 10.2217/fon-2020-0570.
Takemura K, Kawai T, Sato Y, Miyakawa J, Taguchi S, Akiyama Y, Yamada Y, Nakamura M, Yamada D, Suzuki M, Nakagawa T, Kume H. Impact of initial computed tomography findings on management of atypical urinary cytology of the upper urinary tract. Urol Int. 2021;105(7-8):619-623. doi: 10.1159/000512978.
Negishi T, Furubayashi N, Nakagawa T, Nishiyama N, Kitamura H, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, Okajima E, Nakamura M. Site-specific response to nivolumab in renal cell carcinoma. Anticancer Res. 2021;41(3):1539-45. doi:10.21873/anticanres.14913
Wada K, Yokoyama T, Uno S, Araki M, Sadahira T, Maruyama Y, Acosta H, Nakajima H, Hiyama Y, Kunishima Y, Togo Y, Nukaya T, Yamada H, Shigemura K, Ito S, Tanimura M, Kobayashi K, Kitano H, Teishima J, Yasuda M, Watanabe T, Nakagawa T, Hayami H, Miyazaki J, Takahashi S, Masumori N, Ishikawa K, Kiyota H, Fujisawa M, Arakawa S, Nasu Y, Yamamoto S. Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: conducted by the Japanese Research Group for Urinary Tract Infections (JRGU). J Infect Chemother. 2021;27(8):1169-80. doi: 10.1016/j.jiac.2021.03.012.
Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Tabata M, Kaneko T, Taguchi S, Naito A, Hikatsu M, Sato Y, Murata T, Matsumoto A, Miyazaki H, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Takeuchi T, Tanaka Y, Kume H. Smaller decline of renal function after nephroureterectomy predicts poorer prognosis of upper tract urothelial carcinoma: a multi-center retrospective study. Jpn J Clin Oncol. 2021;51(10):1577-1586. doi: 10.1093/jjco/hyab081.
Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y, Ochi Y, Shiozawa Y, Aoki K, Yoshida K, Kataoka K, Nakagawa MM, Nannya Y, Makishima H, Miyakawa J, Kawai T, Morikawa T, Shiraishi Y, Chiba K, Tanaka H, Nagae G, Sanada M, Sugihara E, Sato TA, Nakagawa T, Fukayama M, Ushiku T, Aburatani H, Miyano S, Coleman JA, Homma Y, Solit DB, Kume H, Ogawa S. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell. 2021;39(6):793-809.e8. doi: 10.1016/j.ccell.2021.05.008.
Taguchi S, Kawai T, Nakagawa T, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Takahashi S, Kume H. Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: A multicenter retrospective study. Sci Rep. 2021;11(1):15623. doi: 10.1038/s41598-021-95061-z.
英文、Review Articles
Nakagawa T. Lymph Node Dissection for Bladder Cancer: Current Standards and the Latest Evidence. Int J Urol. 2021;28(1):7-15. doi: 10.1111/iju.14398.
英文、Case Reports
Kaneko T, Sakamoto A, Yoshida T, Yanagida K, Yoshimura I, Hagiwara K, Kimura M, Yamada Y, Nakagawa T. Penetrating penile injury due to the splintering of the floorboards in the gymnasium. IJU Case Rep. 2021;4(4):221-3. doi: 10.1002/iju5.12290.
2020年
英文、原著論文
Kobayashi Y, Yamada D, Kawai T, Sato Y, Teshima T, Yamada Y, Nakamura M, Suzuki M, Matsumoto A, Nakagawa T, Hosoi A, Nagaoka K, Karasaki T, Matsushita H, Kume H, Kakimi K. Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. Int J Oncol. 2020;56:999-1013.
英文、Editorials and Letters
Taguchi S, Nakagawa T, Fukuhara H. Inconsistencies in currently used definitions of sarcopenia in oncology. Ann Oncol. 2020;31:318-9.
英文、Case Reports
Kaneko T, Sakamoto A, Yamada Y, Yamamoto M, Kondo H, Nakagawa T. Uretero-arterial fistula treated with endovascular stent graft following multiple interventions. IJU Case Rep. 2020;3:275-7. doi:10.1002/iju5.12216.
2019年
英文、原著論文
Fujimura T, Igawa Y, Aizawa N, Niimi A, Yamada Y, Sugihara T, Kamei J, Sato Y, Matsunaga A, Yoshida M, Shinoda Y, Fukuhara H, Nakagawa T, Homma Y, Kume H. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy. Neurourol Urodyn. 2019;38(4):1067-1075. doi: 10.1002/nau.23952.
Akiyama Y, Maeda D, Katoh H, Morikawa T, Niimi A, Nomiya A, Sato Y, Kawai T, Goto A, Fujimura T, Fukuhara H, Nakagawa T, Igawa Y, Ishikawa S, Fukayama M, Kume H, Homma Y. Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies. J Urol. 2019;202:290-300. doi: 10.1097/JU.0000000000000234.
Tsumura K, Arai E, Tian Y, Shibuya A, Nishihara H, Yotani T, Yamada Y, Takahashi Y, Maeshima AM, Fujimoto H, Nakagawa T, Kume H, Homma Y, Yoshida T, Kanai Y. Establishment of permutation for cancer risk estimation in the urothelium based on genome-wide DNA methylation analysis. Carcinogenesis. 2019;40:1308-19. doi: 10.1093/carcin/bgz112.
英文、Editorials and Letters
Taguchi S, Nakagawa T, Fukuhara H. Re: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604-11. Eur Urol. 2019;76:e35-e36. doi: 10.1016/j.eururo.2019.04.031.
2018年
英文、原著論文
Makino K, Nakagawa T, Ito E, Kasahara I, Murata T, Fujimura T, Fukuhara H, Homma Y. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/mL or greater. Jpn J Clin Oncol. 2018;48(5):485-90. doi: 10.1093/jjco/hyy044.
Akiyama Y, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Extent of Hunner lesions: The relationships with symptom severity and clinical parameters in Hunner type interstitial cystitis patients. Neurourol Urodyn. 2018 Apr;37(4):1441-1447.
Nakagawa T, Taguchi S, Uemura Y, Kanatani A, Ikeda M, Matsumoto A, Yoshida K, Kawai T, Nagata M, Yamada D, Komemushi Y, Suzuki M, Enomoto Y, Nishimatsu H, Ishikawa A, Nagase Y, Kondo Y, Tanaka Y, Okaneya T, Hirano Y, Shinohara M, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Nomogram for predicting survival of post-cystectomy recurrent urothelial carcinoma of the bladder. Urol Oncol. 2017;35:457.e15-457.e21. doi: 10.1016/j.urolonc.2016.12.010.
Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. World J Urol, 2017 Oct;35(10):1569-1575. doi: 10.1007/s00345-017-2032-6.
Nakagawa T, Taguchi S, Kanatani A, Kawai T, Ikeda M, Urakami S, Matsumoto A, Komemushi Y, Miyakawa J, Yamada D, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Nagase Y, Hirano Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who is the Best Candidate? Ann Surg Oncol. 2017;24:2794-2800. doi: 10.1245/s10434-017-5970-8.
Miyazaki H, Hirano Y, Kato S, Ioritani N, Ichikawa T, Takamoto H, Homma Y. Early Experiences of Contact Laser Vaporization of the Prostate using the 980 nm High Power Diode Laser for Benign Prostatic Hyperplasia Low Urin Tract Symptoms. 2017 Jun 2. doi: 10.1111/luts.12173.
Kimura M, Nagao K, Tai T, Kobayashi H, Nakajima K. Age is a significant predictor of early and late improvement in semen parameters after microsurgical varicocele repair. Andrologia. 2017 Apr;49(3). doi: 10.1111/and.12620.
Akiyama Y, Maeda D, Morikawa T, Niimi A, Nomiya A, Yamada Y, Igawa Y, Goto A, Fukayama M, Homma Y. Digital quantitative analysis of mast cell infiltration in interstitial cystitis. Neurourol Urodyn. 2017 Oct 24 doi: 10.1002/nau.23365.
Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi, S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. World J Urol. 2018;36(2):249-56. doi: 10.1007/s00345-017-2141-2.